polycythemia vera
Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.
Given that the identical somatic activating mutation in the <span class="gene" id="19287384-2-60-64">JAK2</span> tyrosine kinase gene (<span class="gene" id="19287384-2-87-91">JAK2</span>(V617F)) is observed in most individuals with <span class="disease" id="19287384-2-137-154">polycythemia vera</span>, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.